Prenetics Group (PRE)
NASDAQ:PRE
PRE Stock Chart & Stats
$17.73
-$0.22(-3.97%)
At close: 4:00 PM EST
$17.73
-$0.22(-3.97%)
Day’s Range― - ―
52-Week Range$3.45 - $23.63
Previous CloseN/A
Volume5.03K
Average Volume (3M)190.63K
Market Cap
$298.37M
Enterprise Value$219.25M
Total Cash (Recent Filing)$61.49M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Jun 08, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding15,247,465
10 Day Avg. Volume135,028
30 Day Avg. Volume190,635
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.31
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda-5.35
Forecast
1Y Price Target
$32.50Price Target Upside83.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$192.51M
Bulls Say, Bears Say
Bulls Say
Rapid IM8 Scale And Global Revenue TractionIM8’s very fast scale and $120M ARR in <12 months show durable product-market fit and repeat purchasing across geographies. A broad international footprint and recurring subscription mix increase revenue visibility and support sustainable expansion of higher-margin consumer health revenue streams.
Improving Gross Margins And Strong Unit EconomicsSustained gross margins near 60% and unit metrics (LTV:CAC ~3x, ~3.4 month payback) indicate the business can scale without proportionate margin dilution. These economics support profitable unit-level growth and suggest durable operating leverage as marketing efficiency and subscription mix mature.
Strengthened Balance Sheet Via Divestitures And Zero DebtNon-dilutive asset sales and retained liquidity leave the company well-capitalized to fund international expansion, clinical work and marketing without immediate financing. Low leverage reduces balance-sheet risk and gives management time to execute a path to profitability.
Bears Say
Persistent Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow means the business is consuming liquidity to sustain growth. Even with current cash buffers, ongoing cash burn raises reliance on asset sales, capital markets, or tighter margins to fund growth, increasing execution and funding risk over the medium term.
Ongoing Adjusted EBITDA Losses And Delayed ProfitabilityManagement’s plan still implies multi-year adjusted EBITDA losses as the company scales. Delayed operating profitability extends the period of structural loss-making, increasing sensitivity to slower growth or rising CAC and compressing optionality for reinvestment or shareholder returns.
Revenue Concentration In IM8 And Heavy Marketing RelianceHigh concentration in a single brand/product and dependence on aggressive, channel-intensive marketing create structural risk. If acquisition economics worsen or channels shift, revenue growth and margin sustainability could be impaired, challenging the durability of current unit economics.
Prenetics Group News
PRE FAQ
What was Prenetics Group’s price range in the past 12 months?
Prenetics Group lowest stock price was $3.45 and its highest was $23.63 in the past 12 months.
What is Prenetics Group’s market cap?
Prenetics Group’s market cap is $298.37M.
When is Prenetics Group’s upcoming earnings report date?
Prenetics Group’s upcoming earnings report date is Jun 08, 2026 which is in 56 days.
How were Prenetics Group’s earnings last quarter?
Prenetics Group released its earnings results on Feb 18, 2026. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$1.44.
Is Prenetics Group overvalued?
According to Wall Street analysts Prenetics Group’s price is currently Undervalued.
Does Prenetics Group pay dividends?
Prenetics Group pays a Quarterly dividend of $0.7 which represents an annual dividend yield of N/A. See more information on Prenetics Group dividends here
What is Prenetics Group’s EPS estimate?
Prenetics Group’s EPS estimate is -0.82.
How many shares outstanding does Prenetics Group have?
Prenetics Group has 15,247,465 shares outstanding.
What happened to Prenetics Group’s price movement after its last earnings report?
Prenetics Group reported an EPS of -$1.77 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -7.728%.
Which hedge fund is a major shareholder of Prenetics Group?
Currently, no hedge funds are holding shares in PRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prenetics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.50 (83.31% Upside)
$32.50 (83.31% Upside)
Blogger Sentiment
Bullish
PRE Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
398.03%
12-Months-Change
Fundamentals
Return on Equity
-36.02%
Trailing 12-Months
Asset Growth
-4.71%
Trailing 12-Months
Company Description
Prenetics Group
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
PRE Company Deck
PRE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial transformation driven by IM8: exceptional top-line growth (FY revenue +480% YoY), rapid product-market fit (IM8 $120M run rate), improving gross margins (~59% consolidated; IM8 63%), healthy unit economics (LTV:CAC ~3x; payback ~3.4 months) and a fortified balance sheet (~$171M liquidity, 0 debt). Near-term risks include ongoing adjusted EBITDA losses with FY2026 guidance widening to $16M–$20M as the company invests to scale, revenue concentration in IM8 (~65% of FY2025 revenue), historical CAC inefficiency in 2025, reliance on intensive marketing spend, and residual crypto exposure. Overall, the positive growth trajectory, margin profile, and strong liquidity substantially outweigh the near-term profitability and concentration risks.View all PRE earnings summariesPRE Stock 12 Month Forecast
Average Price Target
$32.50
▲(83.31% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.04% Mutual Funds
6.61% Other Institutional Investors
93.13% Public Companies and
Individual Investors